Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Characterisation of the NRF2-mediated anti-oxidant gene battery by transcriptional profiling

ABSTRACT: Transcriptional profiling in HACAT cells using a whole human genome array HACAT cells treated with si RNA against Keap 1 or a scrambled si RNA sequence (Scram) vs HACAT cells mock transfected with lipofectamine (reference control)

ORGANISM(S): Homo sapiens

PROVIDER: GSE17011 | GEO | 2009/08/30

SECONDARY ACCESSION(S): PRJNA117753

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

siRNA profiling of human HACAT cells treated with si RNA against Keap 1 or a scrambled si RNA sequence

Project description:Transcriptional profiling in HACAT cells using a whole human genome array; HACAT cells treated with si RNA against Keap 1 or a scrambled si RNA sequence (Scram) vs HACAT cells mock transfected with lipofectamine (reference control) Experiment Overall Design: 2 biological replicates, 2 technical (dye swap) replicates per treatment.

2009-09-04 | E-GEOD-17011 | biostudies-arrayexpress

S2 cell expression data following DmSTING knockdown and cyclic ci-GMP transfection

Project description:S2 cells were knocked down for DmSTING by RNAi or using scrambled RNAi. Cyclic di-GMP (Biolog C057) was transfected 72h later. Mock transfection was performed using lipofectamine alone. Drosophila genome 2.0 Affymetrix arrays were used to perform gene expression analysis.

2018-06-19 | GSE90443 | GEO

Knocking down the eIF4E gene in HaCaT cells, which M5 stimulates to establish the in vitro psoriasis cell model.

Project description:We transfected keratinocytes cell line (HaCaT cells) with si-NC and si-eIF4E, and added M5 into the cell culture medium to reveal the function of eIF4E in the in vitro psoriasis cell model.

2023-11-22 | GSE247463 | GEO

Effect of FENDRR on genetic expressions of primary liver cancer based on next generation sequencing

Project description:Primary liver cancer (PLC) is the third largest contributor to cancer mortality in the world. PLC is a heterogeneous disease that encompasses several biologically distinct subtypes including hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and combined hepatocellular-cholangiocarcinoma (CHC). The cells were cultured in DMEM medium supplemented with 10% fetal bovine serum and 1% antibiotic-antimitotic solution. The HCC cell line LM3 and ICCA cell line RBE were transfected using Lipofectamine 3000 reagent following the manufacturer’s protocol and incubated for 48h for further analysis. The gene expression profiles were analyzed of LM3 and RBE cells transfected with si-FENDRR or si-NC to assess effect of FENDRR on genetic expressions of PLC.

2021-03-15 | GSE168885 | GEO

Expression data in S2 cells with or without dSTING knockdown followed by dsDNA treatment

Project description:S2 cells were treated with dsRNA targeting dSTING (dSTING RNAi) or non-specifically (control). 90-mer dsDNA (dsDNA90) was then transfected, which activates dSTING. Mock transfection was performed in the absence of dsDNA90 using lipofectamine alone. Affymetrix arrays were used to profile gene expression.

2015-09-22 | GSE54832 | GEO

si RNA interference of Hepatitis B viral gene expression

Project description:Gene expression profiling comparisons of HepG2.2.15 or PLC/PRF/5 cells either mock (M) transfected or transfected with 0.2 microM S2 RNA or Scrambled (SCR) siRNA were carried out in duplicate 48 hours after transfection. The experiments were carried out in duplicate (a and b). The following combinations of RNA were used on 2 slides each: 1. 2.2.15 cells: mock transfection (reference) versus S2 treatment (test) 2. 2.2.15 cells: mock transfection (reference) versus Scr treatment (test) 3. 2.2.15 cells: Scr treatment (reference) versus S2 treatment (test) 4. PLC/PRF/5 cells: mock transfection (reference) versus S2 treatment (test) 5. PLC/PRF/5 cells: mock transfection (reference) versus Scr treatment (test) 6. PLC/PRF/5 cells: Scr treatment (reference) versus S2 treatment (test) A stimulus or stress experiment design type is where that tests response of an organism(s) to stress/stimulus. e.g. osmotic stress, behavioral treatment Keywords: stimulus_or_stress_design

2006-01-07 | GSE3992 | GEO

Transcriptome analysis of immediate early events in mRNA-mediated cellular reprogramming of human foreskin fibroblasts

Project description:In this study human neonatal foreskin fibroblasts (HFF1 and BJ) were lipofected with an equal mixture of human reprogramming factor-encoding mRNAs. The cells were lysed and total RNA was harvested 24 hours post-transfection. Gene regulation was evaluated with respect to corresponding mock-transfected, Lipofectamine-treated control fibroblasts. For comparison, wildtype (un-treated) HFF1 and BJ fibroblasts as well as undifferentiated HFF1- and BJ-derived induced pluripotent stem cells and human embryonic stem cells (generated and maintained in our laboratory (refer to GSE26575) were included in the analysis. Total RNA obtained from untreated human neonatal foreskin fibroblasts, reprogramming factor- and mock(Lipofectamine-treated)-transfected human neonatal fibroblasts, undifferentiated hESCs and iPSCs (derived from human neonatal foreskin fibroblasts).

2012-07-03 | E-GEOD-34943 | biostudies-arrayexpress

Project description:Decoy vs Scrambled and siRNA vs Mock Transfected MBA-MD-231 Cell Line

| PRJNA121129 | ENA

Post-ICB treatment PDAC infiltrating T cells TCR profile

Project description:For the subcutaneous model, 5x105 KPC-Luc cells were injected subcutaneously near the right flank of female C57BL/6 mice. 6-7 days after tumor implantation mice were randomized into 4 treatment groups and treatedwith VIP-R antagonist and/or anti-PD-1. While scram+IgG control mice received scrambled peptide and isotype IgG, the VIP-R antagonist, anti-PD-1 and VIP-R antagonist and anti-PD-1 groups received VIP-R antagonist and IgG; scrambled peptide and anti-PD-1; and VIP-R antagonist and anti-PD-1, respectively. The treatment regimen involved administering 10μg of scrambled or VIP-R antagonist: ANT008, subcutaneously every day and 200μg of IgG or anti-PD-1 intraperitoneally once every three days, for a total of 10 days.

2022-09-19 | GSE213482 | GEO

Transcriptome analysis of immediate early events in mRNA-mediated cellular reprogramming of human foreskin fibroblasts

2012-07-04 | GSE34943 | GEO